Semacare Secures Pre-A Funding Round Led by ISVI to Advance AI-Powered Cardiac Rehabilitation Solutions

VCBeat (WeChat ID: vcbeat) has learned that Semacare, an AI-based medical technology company, recently completed its Pre-A financing round, led by ISVI (Yuanzhen Value Investment), with the investment amount reaching tens of millions of yuan.

Xuhong Medical Technology, formerly known as Senmeijia Medical, was established in Melbourne, Australia, in November 2014. As an innovative medical technology enterprise dedicated to leveraging advanced technologies for life and health data management, the company primarily relies on nanomaterials, machine learning, and other cutting-edge technologies to provide integrated “hardware + software + diagnosis + management” solutions for the cardiovascular field.

Wang Boyang, CEO of Xuhong Medical, has over ten years of experience in the international medical industry. He previously worked in Mindray’s overseas marketing department, serving as General Manager of its Argentina and Australia branches. Wang stated that this round of financing will be primarily used to accelerate team building, product R&D, and market promotion. Xuhong Medical’s products are scheduled to launch this summer, with the goal of reaching more than 200 Grade III Class A hospitals and providing efficient services to 300 million patients and healthcare professionals across China by 2019.

Currently, there are 290 million patients with cardiovascular diseases in China. Cardiovascular disease ranks first in mortality, surpassing cancer and other conditions, and accounts for more than 40% of all disease-related deaths among residents, making it the leading cause of death. However, heart diseases are characterized by their insidious nature, unpredictability, and sudden onset. Traditional devices such as standard electrocardiographs (ECG) and Holter monitors can only provide fragmented or 24–48-hour monitoring. Conventional ECG monitoring often fails to capture electrical activity during symptomatic episodes, hindering effective diagnosis. Moreover, these devices are cumbersome to wear, cause significant discomfort during prolonged use, and are relatively expensive.

Portable remote ECG monitoring technology and long-term monitoring solutions can truly address the needs for cardiac disease monitoring, holding significant practical value. The application of artificial intelligence to transform clinical data from quantitative to qualitative analysis will further enhance the accuracy of clinical diagnoses and disease detection rates. This represents both the development trend in ECG monitoring equipment and the entrepreneurial direction of Xuhong Medical.

Due to the complexity of traditional medical procedures and the limitations of monitoring devices, patients are unable to receive real-time, efficient diagnosis and disease prevention, while physicians struggle to conduct effective follow-ups. Xuhong Medical’s electronic skin-based real-time ECG chest patch, “ZhiXinTie™,” addresses the discomfort associated with long-term use of rigid wearable devices. It enables real-time remote preliminary screening and assists physicians in patient follow-up. Integrated with an AI-powered cloud system, the device provides early warnings to help patients take preventive measures before conditions worsen.

Leveraging millions of precisely annotated data points and hundreds of millions of abnormal samples, Xuhong Medical is currently capable of accurately diagnosing 14 common types of arrhythmias, with accuracy surpassing that of most cardiologists. This achievement is attributed to the company’s “LifeSmart™” technological framework, which corely employs machine learning algorithms—particularly deep recurrent neural networks and attention models—combined with clinical big data-trained algorithms to develop precise automated diagnostic capabilities.

In addition to single-lead ECG chest patches, Xuhong Medical is advancing the development of electronic skin-based dynamic multi-lead Holter monitors. The Holter devices currently provided by hospitals are wired; the cumbersome cables restrict patient mobility, and prolonged wear over multiple days often causes skin irritation, such as redness, swelling, and allergic reactions. Xuhong Medical’s wireless, dynamic multi-lead ECG Holter, leveraging electronic skin sensor technology, effectively addresses issues related to mobility convenience, skin-friendliness, and real-time data transmission. This represents a significant breakthrough in an area where traditional medical devices have seen little innovation for many years.

Xuhong Medical’s software products are divided into two components: Life Study™ and Life Service™. Life Study™ is a professional big data analytics software designed for healthcare institutions, enabling them to deepen and broaden their capabilities in data analysis, mining, and academic research projects. It enhances efficiency and precision while reducing human resource costs for healthcare institutions.

Life Service™ is an initiative by Xuhong Medical that leverages artificial intelligence algorithms and medical expertise to enable third parties to develop healthcare-grade health data applications. For instance, Xuhong Medical has collaborated with leading industry enterprises both in China and abroad. By using these partners’ wearable devices, users can receive real-time detection of cardiac abnormalities, such as atrial fibrillation and arrhythmia, and be referred to third-party medical institutions for consultation and feedback.

Lai Runwei, Founding Partner of Yuanzhen Value Investment, stated, “The founding team of Xuhong Medical comprises R&D experts in innovative medical hardware and software as well as seasoned marketing professionals from around the world. United by a shared vision and original aspiration, the team demonstrates strong cohesion and total dedication, making it a truly exemplary ‘all-in’ entrepreneurial team. Their adherence to the core philosophy of ‘people-centricity, leveraging innovative technology to enable healthier and better lives’ aligns perfectly with Yuanzhen’s investment principles.”

In terms of product offerings, Yuanzhen Capital believes that Xuhong Medical’s use of innovative electronic skin materials and breathable designs delivers superior user experience and aesthetics. Technologies such as the Internet of Things (IoT) and AI algorithms ensure diagnostic efficiency and accuracy, making its products competitive within their category. The combination of Life Study™ (a data science product), Life Service™ (a data services product), and hardware products (for front-end data detection and diagnosis) enables an integrated service model encompassing cardiovascular disease prevention, automated preliminary screening, and treatment planning. This approach facilitates a significant upgrade in cardiovascular diagnosis and treatment models, creates differentiation, and establishes a closed-loop commercial ecosystem for its products.

However, the true implementation of AI in healthcare hinges on real-world application scenarios. It remains challenging for technology companies or medical institutions operating in isolation to achieve significant breakthroughs in artificial intelligence-driven healthcare. Xuhong Medical has established deep collaborations with multiple leading medical institutions, including the First Affiliated Hospital of Dalian Medical University, Beijing 301 Hospital (PLA General Hospital), Kailuan General Hospital, Meinian Onehealth, and Australia’s Baker IDI Heart and Diabetes Institute. Through these partnerships, the company has identified critical unmet clinical needs, secured access to sustainable, high-quality medical data and resources, developed leading algorithmic models, and obtained a substantial volume of potential sales orders.